Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 8/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CCRL2 | O00421 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826398 | 1.00 | OPRL1 (0.47) | OPRL1KDM4CKDM4ESYKCYP2C19 | |
| SCHEMBL15826397 | 1.00 | OPRL1 (0.47) | OPRL1KDM4CKDM4ESYKCYP2C19 | |
| SCHEMBL15821361 | 0.88 | OPRL1 (0.40) | OPRL1KDM4CKDM4ESYKCYP2C19 | |
| SCHEMBL15823793 | 0.79 | SYK (0.44) | OPRL1KDM4ESYKCYP2C19 | |
| SCHEMBL15823795 | 0.79 | SYK (0.44) | OPRL1KDM4ESYKCYP2C19 | |
| SCHEMBL15823794 | 0.79 | SYK (0.44) | OPRL1KDM4ESYKCYP2C19 | |
| SCHEMBL2038699 | 0.79 | SYK (0.42) | OPRL1SYKCCR2KCNH2CCRL2 | |
| SCHEMBL17151565 | 0.79 | OPRL1 (0.47) | OPRL1CYP2C19CCR2KCNH2CCRL2 | |
| SCHEMBL12632466 | 0.77 | SYK (0.47) | SYK | |
| SCHEMBL12194315 | 0.77 | SYK (0.47) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934525-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014100314-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | OPRL1 2355/4885KDM4C 1407/4885KDM4E 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.